ANTENGENE-B Shares Surge Over 11% at Open on UCB Licensing Deal for CD19/CD3 Bispecific Antibody

Stock News

Yesterday

ANTENGENE-B (06996) opened more than 11% higher. At the time of writing, the stock was up 11.11% at HK$3.2, with a turnover of HK$659,200. The move follows an announcement that ANTENGENE and UCB have entered into an agreement. Under the terms, ANTENGENE grants UCB exclusive global rights to develop, manufacture, and commercialize the CD19/CD3 bispecific T-cell engager antibody ATG-201, including related production technology licenses. ANTENGENE will receive a total of $80 million, comprising a $60 million upfront payment and an additional $20 million in near-term milestone payments. The company is also eligible for up to over $1.1 billion in future milestone payments, plus tiered royalties based on future net sales. ANTENGENE plans to submit a clinical trial application for ATG-201 in China and Australia in the first quarter of 2026 and will conduct the first-in-human (Phase I) clinical study in these regions. Subsequent clinical development and related activities for ATG-201 will then be transferred to UCB.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1165898043"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1165898043\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1165898043?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 09:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165898043","market":"sg","top_or_hot":-1,"title":"ANTENGENE-B Shares Surge Over 11% at Open on UCB Licensing Deal for CD19/CD3 Bispecific Antibody","media":"Stock News","content":"<p>ANTENGENE-B (06996) opened more than 11% higher. At the time of writing, the stock was up 11.11% at HK$3.2, with a turnover of HK$659,200. The move follows an announcement that ANTENGENE and UCB have entered into an agreement. Under the terms, ANTENGENE grants UCB exclusive global rights to develop, manufacture, and commercialize the CD19/CD3 bispecific T-cell engager antibody ATG-201, including related production technology licenses. ANTENGENE will receive a total of $80 million, comprising a $60 million upfront payment and an additional $20 million in near-term milestone payments. The company is also eligible for up to over $1.1 billion in future milestone payments, plus tiered royalties based on future net sales. ANTENGENE plans to submit a clinical trial application for ATG-201 in China and Australia in the first quarter of 2026 and will conduct the first-in-human (Phase I) clinical study in these regions. Subsequent clinical development and related activities for ATG-201 will then be transferred to UCB.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ANTENGENE-B Shares Surge Over 11% at Open on UCB Licensing Deal for CD19/CD3 Bispecific Antibody</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nANTENGENE-B Shares Surge Over 11% at Open on UCB Licensing Deal for CD19/CD3 Bispecific Antibody\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-04 09:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ANTENGENE-B (06996) opened more than 11% higher. At the time of writing, the stock was up 11.11% at HK$3.2, with a turnover of HK$659,200. The move follows an announcement that ANTENGENE and UCB have entered into an agreement. Under the terms, ANTENGENE grants UCB exclusive global rights to develop, manufacture, and commercialize the CD19/CD3 bispecific T-cell engager antibody ATG-201, including related production technology licenses. ANTENGENE will receive a total of $80 million, comprising a $60 million upfront payment and an additional $20 million in near-term milestone payments. The company is also eligible for up to over $1.1 billion in future milestone payments, plus tiered royalties based on future net sales. ANTENGENE plans to submit a clinical trial application for ATG-201 in China and Australia in the first quarter of 2026 and will conduct the first-in-human (Phase I) clinical study in these regions. Subsequent clinical development and related activities for ATG-201 will then be transferred to UCB.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"","article_id":"1165898043","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165898043","pubTimestamp":1772587817,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ANTENGENE-B (06996) opened more than 11% higher. At the time of writing, the stock was up 11.11% at HK$3.2, with a turnover of HK$659,200. The move follows an announcement that ANTENGENE and UCB have...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","VT":"世界全股市ETF-Vanguard","VXUS":"国际股票ETF-Vanguard","06996":"德琪医药-B","BK4588":"碎股","BK1191":"制药","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股"},"translate_title":"德琪-B股价因UCB CD19/CD3双特异性抗体许可协议开盘飙升逾11%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"06996":1,"VT":1},"content_text":"ANTENGENE-B (06996) opened more than 11% higher. At the time of writing, the stock was up 11.11% at HK$3.2, with a turnover of HK$659,200. The move follows an announcement that ANTENGENE and UCB have entered into an agreement. Under the terms, ANTENGENE grants UCB exclusive global rights to develop, manufacture, and commercialize the CD19/CD3 bispecific T-cell engager antibody ATG-201, including related production technology licenses. ANTENGENE will receive a total of $80 million, comprising a $60 million upfront payment and an additional $20 million in near-term milestone payments. The company is also eligible for up to over $1.1 billion in future milestone payments, plus tiered royalties based on future net sales. ANTENGENE plans to submit a clinical trial application for ATG-201 in China and Australia in the first quarter of 2026 and will conduct the first-in-human (Phase I) clinical study in these regions. Subsequent clinical development and related activities for ATG-201 will then be transferred to UCB.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}